| Full Name | Amber Dayhuff |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 27 W Park St, Butte, Montana |
| Authorized Official Name and Position | Amber Dawn Dayhuff (OWNER) |
| Authorized Official Contact | 4064911313 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Amber Dayhuff 27 W Park St Ste 3 Butte MT 59701-1722 Ph: () - | Amber Dayhuff 27 W Park St Butte MT 59701-1722 Ph: (406) 491-1313 |
| NPI Number | 1619583598 |
|---|---|
| Provider Enumeration Date | 09/16/2020 |
| Last Update Date | 11/27/2023 |
| Certification Date | 11/27/2023 |
| Medicare PECOS PAC ID | 4587016456 |
|---|---|
| Medicare Enrollment ID | O20240116002871 |
News Archive
A new study by the Australian Medical Association (AMA) has found close to half of Australia's junior doctors think their heavy workload could compromise patient care.
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
Porvair Sciences has published a new guide to help laboratories choose the best way to verify the quality and quantity of their Chromatin Immunoprecipitation (ChIP) DNA.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619583598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| Provider Name | Amber D Dayhuff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861849549 PECOS PAC ID: 5294026829 Enrollment ID: I20160628003157 |
News Archive
A new study by the Australian Medical Association (AMA) has found close to half of Australia's junior doctors think their heavy workload could compromise patient care.
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
Porvair Sciences has published a new guide to help laboratories choose the best way to verify the quality and quantity of their Chromatin Immunoprecipitation (ChIP) DNA.
› Verified 2 days ago
News Archive
A new study by the Australian Medical Association (AMA) has found close to half of Australia's junior doctors think their heavy workload could compromise patient care.
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
Porvair Sciences has published a new guide to help laboratories choose the best way to verify the quality and quantity of their Chromatin Immunoprecipitation (ChIP) DNA.
› Verified 2 days ago
Meadow Creek Mental Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 E Front St Ste 517, Butte, MT 59701 Phone: 406-565-5154 Fax: 406-565-5040 | |
Southwest Montana Neuropsychology Services, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 800 W Platinum St Ste F, Butte, MT 59701 Phone: 406-782-4597 Fax: 406-782-1347 | |
Silver Bow Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1229 Harrison Ave, Butte, MT 59701 Phone: 406-590-2747 | |
Dr. Marla Lemons Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 125 W Granite St, Butte, MT 59701 Phone: 406-498-6929 Fax: 406-723-5406 | |
A Better Life Therapeutic Services, P.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1729 Florence Ave, Butte, MT 59701 Phone: 406-565-5583 Fax: 406-565-5584 | |
Cccs Smart Program Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 630 W Mercury St, Butte, MT 59701 Phone: 406-299-3448 Fax: 406-299-3450 | |
Butte School District #1 Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1050 S Montana St, Butte, MT 59701 Phone: 406-533-2969 Fax: 406-533-2980 |